Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development and subsequent commercialization of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases.
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma. The company is also developing KPT-8602 that is in Phase 1/2 study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.
(Summary) (Company) (Chart)
| 22 April 2018 Price $14.59 1yr Target $20.18 Analysts 11 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain % Yield 0.00% 1yr Tot Return % P/E --- PEG --- Beta 3.61 | EPS (ttm) $-2.81 EPS next yr $-2.56 Forward P/E --- EPS next 5yr --- 1yr Price Support --- Market Cap $730.38 Mil Revenues $1.60 Mil Earnings $-129.00 Mil Profit Margin --- Quick Ratio 3.00 Current Ratio 3.00 Debt/Equity --- | 1yr RevGR % 3yr RevGR % 5yr RevGR % 1yr EarnGR % 3yr EarnGR % 5yr EarnGR % 1yr DivGR % 3yr DivGR % 5yr DivGR % ROA -75.30% ROE -89.60% |
Operations
The Company's scientific expertise is focused on understanding the regulation of intracellular communication between the nucleus and the cytoplasm. They've developing novel, small molecule Selective Inhibitor of Nuclear Export, or SINE, compounds that inhibit the nuclear export protein XPO1. These SINE compounds represent a new class of drug candidates with a novel mechanism of action that have the potential to treat a variety of diseases in areas of unmet medical need.
Their lead drug candidate, selinexor (KPT-330), is an XPO1 inhibitor being evaluated in multiple late stage clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. XPO1 mediates the export of over 220 different cargo proteins, including the vast majority of tumor suppressor proteins. Karyopharm believes that no currently approved or current clinical-stage experimental cancer drug candidates are selectively targeting the restoration and increase in the levels of multiple tumor suppressor proteins in the nucleus.
Other drug candidates in development include oral verdinexor (KPT-335), an anti-viral agent as well as a treatment for cancer in companion dogs, oral KPT-350, a treatment for neurological, inflammatory and autoimmune conditions, KPT-8602, a treatment for relapsed/refractory multiple myeloma and an oral dual PAK4/NAMPT inhibitor, KPT-9274, for the treatment of patients with advanced solid malignancies or non-Hodgkin’s lymphoma.
XPO1-inhibiting SINE compounds that the Company has discovered and developed to date, including selinexor, have the potential to provide a novel targeted therapy that enable tumor suppressor proteins to remain in the nucleus and promote apoptosis of cancer cells. The Company believes their SINE compounds have the potential to provide therapeutic benefit in a number of additional indications, including autoimmune and inflammatory diseases, wound healing, HIV and influenza.
In addition to the SINE compounds, the Company also investigates XPO1 cargo proteins and their role in the cell cycle and cell division. As part of this investigation, Karyopharm has identified several XPO1 cargo proteins whose inhibition leads to the selective death of cancer cells. One of the XPO1 cargo proteins is p21-activated kinase 4, or PAK4. PAK4 is a member of the PAK family of kinases that includes 6 proteins, PAK1-6. PAK4-6 belong to a growth-promoting sub-family. PAK4 is a signaling protein regulating numerous fundamental cellular processes, including intracellular transport, cellular division, cell shape and motility, cell survival, immune defense and the development of cancer. PAK4 interacts with many key signaling molecules involved in cancer such as beta-catenin, CDC42, Raf-1, BAD and myosin light chain. Based on this biology, the Company used their drug discovery and optimization expertise to identify small molecule modulators of PAK4. The PAK4 allosteric modulators have shown broad evidence of anti-cancer activity against hematological and solid tumor malignant cells while showing minimal toxicity to normal cells in vitro. In mouse and rat xenograft studies, the PAK4 inhibitors given orally have shown evidence of anti-cancer activity and tolerability.
Recently, Karyopharm identified an additional target for their clinical candidate KPT-9274 known as NAMPT (Nicotinamide phosphoribosyltransferase; also known as PBEF or Visfatin). NAMPT is a pleiotropic protein with intra- and extra-cellular functions as an enzyme, cytokine, growth factor, and hormone that can be found in complex with PAK4 in the cell. NAMPT is of interest as an oncology target because it catalyzes the rate-limiting step in one of the two intracellular salvage pathways that generate nicotinamide adenine dinucleotide, or NAD. NAD is a universal energy- and signal-carrying molecule involved in mitochondrial function, energy metabolism, calcium homeostasis, antioxidation, and paradoxically generation of oxidative stress, gene expression, immunological functions, aging, and cell death.
In addition, the Company is investigating a SINE compound for cancer in companion dogs, both as a surrogate model for human malignancies and as a potential treatment for cancers in dogs. It is widely known that canine lymphomas respond to chemotherapy similarly to their human counterpart (human NHL) and display a comparable genetic profile. Lymphomas are one of the most common tumors in pet dogs. Lymphoma in dogs is very aggressive and, without treatment, the tumors are often fatal within weeks. The majority of dog lymphomas are DLBCL and most of the others are T-cell lymphomas. Verdinexor has received a Minor Use / Minor Species, or MUMS, designation from the Center for Veterinary Medicine, or CVM, of the FDA for the treatment of lymphomas in canines.
The Company's scientific expertise is focused on understanding the regulation of intracellular communication between the nucleus and the cytoplasm. They've developing novel, small molecule Selective Inhibitor of Nuclear Export, or SINE, compounds that inhibit the nuclear export protein XPO1. These SINE compounds represent a new class of drug candidates with a novel mechanism of action that have the potential to treat a variety of diseases in areas of unmet medical need.
Their lead drug candidate, selinexor (KPT-330), is an XPO1 inhibitor being evaluated in multiple late stage clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. XPO1 mediates the export of over 220 different cargo proteins, including the vast majority of tumor suppressor proteins. Karyopharm believes that no currently approved or current clinical-stage experimental cancer drug candidates are selectively targeting the restoration and increase in the levels of multiple tumor suppressor proteins in the nucleus.
Other drug candidates in development include oral verdinexor (KPT-335), an anti-viral agent as well as a treatment for cancer in companion dogs, oral KPT-350, a treatment for neurological, inflammatory and autoimmune conditions, KPT-8602, a treatment for relapsed/refractory multiple myeloma and an oral dual PAK4/NAMPT inhibitor, KPT-9274, for the treatment of patients with advanced solid malignancies or non-Hodgkin’s lymphoma.
XPO1-inhibiting SINE compounds that the Company has discovered and developed to date, including selinexor, have the potential to provide a novel targeted therapy that enable tumor suppressor proteins to remain in the nucleus and promote apoptosis of cancer cells. The Company believes their SINE compounds have the potential to provide therapeutic benefit in a number of additional indications, including autoimmune and inflammatory diseases, wound healing, HIV and influenza.
In addition to the SINE compounds, the Company also investigates XPO1 cargo proteins and their role in the cell cycle and cell division. As part of this investigation, Karyopharm has identified several XPO1 cargo proteins whose inhibition leads to the selective death of cancer cells. One of the XPO1 cargo proteins is p21-activated kinase 4, or PAK4. PAK4 is a member of the PAK family of kinases that includes 6 proteins, PAK1-6. PAK4-6 belong to a growth-promoting sub-family. PAK4 is a signaling protein regulating numerous fundamental cellular processes, including intracellular transport, cellular division, cell shape and motility, cell survival, immune defense and the development of cancer. PAK4 interacts with many key signaling molecules involved in cancer such as beta-catenin, CDC42, Raf-1, BAD and myosin light chain. Based on this biology, the Company used their drug discovery and optimization expertise to identify small molecule modulators of PAK4. The PAK4 allosteric modulators have shown broad evidence of anti-cancer activity against hematological and solid tumor malignant cells while showing minimal toxicity to normal cells in vitro. In mouse and rat xenograft studies, the PAK4 inhibitors given orally have shown evidence of anti-cancer activity and tolerability.
Recently, Karyopharm identified an additional target for their clinical candidate KPT-9274 known as NAMPT (Nicotinamide phosphoribosyltransferase; also known as PBEF or Visfatin). NAMPT is a pleiotropic protein with intra- and extra-cellular functions as an enzyme, cytokine, growth factor, and hormone that can be found in complex with PAK4 in the cell. NAMPT is of interest as an oncology target because it catalyzes the rate-limiting step in one of the two intracellular salvage pathways that generate nicotinamide adenine dinucleotide, or NAD. NAD is a universal energy- and signal-carrying molecule involved in mitochondrial function, energy metabolism, calcium homeostasis, antioxidation, and paradoxically generation of oxidative stress, gene expression, immunological functions, aging, and cell death.
In addition, the Company is investigating a SINE compound for cancer in companion dogs, both as a surrogate model for human malignancies and as a potential treatment for cancers in dogs. It is widely known that canine lymphomas respond to chemotherapy similarly to their human counterpart (human NHL) and display a comparable genetic profile. Lymphomas are one of the most common tumors in pet dogs. Lymphoma in dogs is very aggressive and, without treatment, the tumors are often fatal within weeks. The majority of dog lymphomas are DLBCL and most of the others are T-cell lymphomas. Verdinexor has received a Minor Use / Minor Species, or MUMS, designation from the Center for Veterinary Medicine, or CVM, of the FDA for the treatment of lymphomas in canines.
Click to Enlarge
My Path Forward
I actually found this company researching options and reviewing stock charts. This one looked really interesting and the premiums were rather robust. That said, there's always a lot of risk involved in biotechnology stocks and even more so in those clinical stage companies without an approved product. So obviously, Karyopharm is a very risky investment.
I intend to start a postion in these shares and then immediately sell puts and options on the position. The purpose is to receive option income quickly to offset the price of the shares and hopefully get reimbursed as quickly as possible for the outlay of money for the position. Assuming I can bracket the movement correctly, I'll keep the premium income without loosing the shares. Additional income or wealth will come from the increase in the value of the shares over time and the risk is the possible reduction in the value of the shares faster than the inflow of income from the options.
This can be a very lucrative strategy over time but it can also be expensive if the shares decide to move against the trader. Therefore any investor making this type of investment should have an exit strategy in place at the time of entry.
I actually found this company researching options and reviewing stock charts. This one looked really interesting and the premiums were rather robust. That said, there's always a lot of risk involved in biotechnology stocks and even more so in those clinical stage companies without an approved product. So obviously, Karyopharm is a very risky investment.
I intend to start a postion in these shares and then immediately sell puts and options on the position. The purpose is to receive option income quickly to offset the price of the shares and hopefully get reimbursed as quickly as possible for the outlay of money for the position. Assuming I can bracket the movement correctly, I'll keep the premium income without loosing the shares. Additional income or wealth will come from the increase in the value of the shares over time and the risk is the possible reduction in the value of the shares faster than the inflow of income from the options.
This can be a very lucrative strategy over time but it can also be expensive if the shares decide to move against the trader. Therefore any investor making this type of investment should have an exit strategy in place at the time of entry.
Print 
PDF
RSS Feed
